Literature DB >> 31168256

Isolated Metastases to Multiple Genital Organs: a Curious Case of Metachronous Spread of Carcinoma Colon.

Saheer N1, Prasanth Penumadu1, Ashwani Kumar Sachdeva2, Pavneet Singh Kohli1.   

Abstract

Entities:  

Year:  2019        PMID: 31168256      PMCID: PMC6527616          DOI: 10.1007/s13193-018-0855-2

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


× No keyword cloud information.
  15 in total

Review 1.  Biology and significance of circulating and disseminated tumour cells in colorectal cancer.

Authors:  Gunnar Steinert; Sebastian Schölch; Moritz Koch; Jürgen Weitz
Journal:  Langenbecks Arch Surg       Date:  2012-02-15       Impact factor: 3.445

2.  Epidemiology and prognosis of ovarian metastases in colorectal cancer.

Authors:  J Segelman; A Flöter-Rådestad; H Hellborg; A Sjövall; A Martling
Journal:  Br J Surg       Date:  2010-11       Impact factor: 6.939

3.  Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary.

Authors:  Christopher R Garrett; Ben George; Chitra Viswanathan; Nishin A Bhadkamkar; Sijin Wen; Veerarabhadran Baladandayuthapani; Y Nancy You; Edmund S Kopetz; Michael J Overman; Bryan K Kee; Cathy Eng
Journal:  Clin Colorectal Cancer       Date:  2012-01-26       Impact factor: 4.481

4.  Vaginal metastasis revealing colon adenocarcinoma.

Authors:  Frédéric Marchal; Agnès Leroux; Sylvette Hoffstetter; Perrine Granger
Journal:  Int J Colorectal Dis       Date:  2005-06-18       Impact factor: 2.571

5.  Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Authors:  Andrea Sartore-Bianchi; Livio Trusolino; Cosimo Martino; Katia Bencardino; Sara Lonardi; Francesca Bergamo; Vittorina Zagonel; Francesco Leone; Ilaria Depetris; Erika Martinelli; Teresa Troiani; Fortunato Ciardiello; Patrizia Racca; Andrea Bertotti; Giulia Siravegna; Valter Torri; Alessio Amatu; Silvia Ghezzi; Giovanna Marrapese; Laura Palmeri; Emanuele Valtorta; Andrea Cassingena; Calogero Lauricella; Angelo Vanzulli; Daniele Regge; Silvio Veronese; Paolo M Comoglio; Alberto Bardelli; Silvia Marsoni; Salvatore Siena
Journal:  Lancet Oncol       Date:  2016-04-20       Impact factor: 41.316

6.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Authors:  Ki Young Chung; Jinru Shia; Nancy E Kemeny; Manish Shah; Gary K Schwartz; Archie Tse; Audrey Hamilton; Dorothy Pan; Deborah Schrag; Lawrence Schwartz; David S Klimstra; Daniel Fridman; David P Kelsen; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2005-01-27       Impact factor: 44.544

7.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

8.  Ovarian metastases in colorectal cancer.

Authors:  Ramesh Omranipour; Abolghasem Abasahl
Journal:  Int J Gynecol Cancer       Date:  2009-12       Impact factor: 3.437

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 10.  Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.

Authors:  A Rowland; M M Dias; M D Wiese; G Kichenadasse; R A McKinnon; C S Karapetis; M J Sorich
Journal:  Br J Cancer       Date:  2015-05-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.